Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer-Reference-Cited by-同舟云学术

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

Published:2011-05 Issue:5 Volume:19 Page:575-586
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Carver Brett S.,Chapinski Caren,Wongvipat John,Hieronymus Haley,Chen Yu,Chandarlapaty Sarat,Arora Vivek K.,Le Carl,Koutcher Jason,Scher Howard,Scardino Peter T.,Rosen Neal,Sawyers Charles L.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference46 articles.

1. Cancer Facts and Figures 2010,2010

2. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells;Brachmann;Proc. Natl. Acad. Sci. USA,2009

3. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer;Carracedo;J. Clin. Invest.,2008

4. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity;Chandarlapaty;Cancer Cell,2011

5. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis;Chen;Nature,2005

Cited by 997 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insulin-related traits and prostate cancer: A Mendelian randomization study;Computational and Structural Biotechnology Journal;2024-12

2. PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway;Neoplasia;2024-11

3. “One Method to Label Them All”: A Single Fully Automated Protocol for GMP-Compliant ⁶⁸Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617;Current Radiopharmaceuticals;2024-09

4. Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.;Cancer Letters;2024-09

5. Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway;Molecular Oncology;2024-08-02